A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies
NCT ID: NCT00051597
Last Updated: 2011-10-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
70 participants
INTERVENTIONAL
2003-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a single-arm, open-label phase I/II study designed to define the toxicity profile, pharmacokinetic (PK) profile, and anti-tumor activity of a multi-dose regimen of SGN-30 in patients with refractory or recurrent CD30+ hematologic malignancies. The phase I study will be a modified dose escalation of SGN-30. Based on preclinical pharmacology and toxicokinetics (TK) and the first use in human single-dose phase I study, SGN-30 will be administered on a weekly schedule. An initial dose of 2 mg/kg will escalate until the maximum tolerated dose (MTD) has been reached or until a weekly dose of 12 mg/kg is achieved.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SGN-30 (monoclonal antibody)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Patients must have at least one of the following:
* Patients with HD must have failed systemic chemotherapy either as initial therapy for advanced stage disease or as salvage therapy after initial radiotherapy (XRT) for early stage disease and be ineligible for, or refuse treatment by stem cell transplantation
* Patients with other CD30+ malignancies must be beyond 1st remission or refractory to front line chemotherapy
* Patients with refractory or chemo-resistant multiple myeloma (MM), as defined by a failure to respond (\<50% reduction in M-protein level), or disease progression less than 2 months after receiving at least two conventional chemotherapy regimens
* Patients with MM in the Plateau Phase of their disease may be included in the study. Plateau phase will be defined as persistent (more than 6 weeks) M-protein in the serum or urine despite a significant initial reduction (\>50%) in response to previous therapy. These patients should have received at least two of the conventional chemotherapy regimens listed above prior to enrollment in this study.
* Patients with relapsed MM as defined by disease progression more than 2 months after initial therapy and subsequent failure to respond (\<50% reduction or progression in M-protein levels) to ONE of the above listed regimens or other salvage regimens (high dose cyclophosphamide, topotecan).
Patients must have at least one of the following:
* Bidimensional or unidimensional measurable disease on physical examination or radiologic evaluation
* Circulating tumor cells in peripheral blood
* Evidence of bone marrow disease to any degree in patients with HD
* \>10% tumor cells in bone marrow in patients with other CD30+ malignancies
* Minimum of 4 weeks from last therapy (including radiotherapy or chemotherapy); a minimum of 6 weeks from last treatment with nitrogen mustard agents, melphalan or BCNU
* ECOG performance status ≤ 2 (Appendix B) with a life expectancy \> 3 months
Exclusion Criteria
* Symptomatic cardiac disease including ventricular dysfunction, coronary artery disease or arrhythmias
* More than one primary malignancy with the exception of non-melanoma skin cancer or cervical carcinoma in situ (CIN) on a biopsy or squamous intraepithelial lesion (SIL) on PAP smear
* Active viral, bacterial, or systemic fungal infection including known HIV positivity
* Symptomatic brain metastases requiring treatment
* Concurrent therapy with other anti-neoplastic agents, corticosteroids, or experimental agents
* Any serious underlying medical condition which would impair the ability of the patient to receive or tolerate the planned treatment including prior allergic reactions to recombinant human or murine proteins
* Receipt of any therapeutic mAbs within 6 months unless a recent serum testing reveals no antibody titer and no evidence of anti-chimeric or anti-murine antibody in the peripheral circulation
* Female patients who are pregnant or breastfeeding
* Dementia or altered mental status that would prohibit the understanding and rendering of informed consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seagen Inc.
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amy P Sing, MD
Role: STUDY_DIRECTOR
Seagen Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama, Birmingham
Birmingham, Alabama, United States
USC Norris Cancer Center
Los Angeles, California, United States
University of Miami
Miami, Florida, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Siteman Cancer Center
St Louis, Missouri, United States
University of Nebraska
Omaha, Nebraska, United States
Cornell Medical College, New York Presbyterian
New York, New York, United States
University of Rochester
Rochester, New York, United States
MD Anderson Cancer Center
Houston, Texas, United States
University of Washington
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bartlett NL, Younes A, Carabasi MH, Forero A, Rosenblatt JD, Leonard JP, Bernstein SH, Bociek RG, Lorenz JM, Hart BW, Barton J. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood. 2008 Feb 15;111(4):1848-54. doi: 10.1182/blood-2007-07-099317. Epub 2007 Dec 13.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SG030-0002
Identifier Type: -
Identifier Source: org_study_id